Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Kailera Therapeutics and its China partner Hengrui have released top-line results from a phase 2 trial of their oral version of ribupatide, which indicate it has a “potentially game-changing clinical profile,” according to Kailera’s chief medical officer Scott Wasserman, M.D.
Resonate Group, an ambitious Nigerian indigenous company with global aspirations, that aligns her vision with strategic intent to provide innovative solutions and services in Oil & Gas, Maritime, Manufacturing, Finance, Steel, Healthcare, and Supply Chain sectors of the Nigerian economy...
